SCHEMBL18110384

SCHEMBL18110384

CN[C@H](C(=O)O)[C@H](O)[C@H](C)CCCc1ccc(F)cn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.34
MAPK1 P28482 1/20 0.33
DAO P14920 1/20 0.33
ADORA2A P29274 1/20 0.33
DGAT1 O75907 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
CACNA1B Q00975 2/20 0.32
APLNR P35414 1/20 0.32
NTRK1 P04629 3/20 0.31
ITGB1 P05556 1/20 0.31
ITGA5 P08648 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP7 P09237 1/20 0.31
MMP9 P14780 1/20 0.31
MMP13 P45452 1/20 0.31
ADORA2B P29275 1/20 0.31
FFAR2 O15552 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18110365 0.85 MCHR1 (0.36) ADORA2ADGAT1MMP1MMP2MMP3
SCHEMBL18110340 0.82 CYP1A2 (0.45)
SCHEMBL18110415 0.80 LMNA (0.35)
SCHEMBL18110372 0.79 CYP1A2 (0.44)
SCHEMBL18110371 0.76 CYP2C9 (0.38)
SCHEMBL18110355 0.76 CYP1A2 (0.42) MAPK1
SCHEMBL18110361 0.76 EPHX2 (0.34)
SCHEMBL18112891 0.76 SMN1; SMN2 (0.33) MMP1MMP9
SCHEMBL18110380 0.76 SMN1; SMN2 (0.33) MMP1MMP9
SCHEMBL18127461 0.76 APLNR (0.36) HTR2ADAOADORA2ACNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077289-B2 Cyclosporins modified on the MeBmt sidechain by heterocyclic rings ALLERGAN, INC. (US) 2018-09-18 US disclosed
EP-3277704-A1 CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS ALLERGAN, INC. (US) 2018-02-07 EP disclosed
WO-2016160362-A1 CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS ALLERGAN, INC. (US) 2016-10-06 WO disclosed
US-20160289271-A1 Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings ALLERGAN, INC. 2016-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077289-B2 Cyclosporins modified on the MeBmt sidechain by heterocyclic rings CHP1, UACA, CRYAB HTR2A 2731/4885MAPK1 3182/4885DAO 3840/4885
US-20160289271-A1 Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings CHP1, UACA, CRYAB HTR2A 2731/4885MAPK1 3182/4885DAO 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.